COVID-19 Seroprevalence in Pregnant Women and Blood Donors (CoVERED)
SARS-CoV-2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Noémie Nminej
- Phone Number: +333 81 21 85 18
- Email: nmninej@chu-besancon.fr
Study Locations
-
-
-
Besançon, France
- CHU de Besançon
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Pregnant women
- Adult female
- Admitted to hospital for live birth
- Informed consent
- Affiliated to the French social security health insurance scheme
Blood donors
- Adult male or female
- Qualified for whole blood donation (up to 70 years old in France)
- Informed consent
- Affiliated to the French social security health insurance scheme
Exclusion Criteria:
- Legal incapacity or limited legal capacity
- Subject without health insurance coverage
- Exclusion period of another study or exclusion period of the French national healthy volunteer registry
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Pregnant women
Women admitted to hospital for a live birth.
|
|
Blood donors
Subjects qualified for whole blood donation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anti-SARS-CoV-2 spike protein total IgG
Time Frame: at inclusion
|
Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay
|
at inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anti-SARS-CoV-2 nucleocapsid protein total IgG
Time Frame: at inclusion
|
Total IgG directed against anti-SARS-CoV-2 nucleocapsid protein as measured by ELISA assay
|
at inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Maxime Desmarets, MD, PhD, CHU Besançon
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021/601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.